Nimodipine in human alcohol withdrawal syndrome — an open study

https://doi.org/10.1016/0924-977X(90)90008-XGet rights and content

Abstract

The aim of this study was to evaluate the efficacy and tolerability of the DHP Ca2+ antagonist nimodipine in human AWS and post-AWS. Ten hospitalized alcoholics of both sexes with a diagnosis of AWS according to the DSM-III criteria were treated for 3 weeks in monotherapy with nimodipine p.o. at flexible daily dosages. Evaluation of AWS symptoms was performed at baseline and after 3, 5, 7, 10, 14 and 21 days. A statistically significant improvement of AWS was seen at evaluation on day 3, particularly in neurovegetative and psychopathological symptoms, and lasted up to the end of the study. The treatment was well tolerated and no side effects were observed or reported. In this pilot, open study nimodipine proved effective in the treatment of mild-to-moderate AWS. If these data are comfirmed in a double-blind study nimodipine could be a rational alternative to benzodiazepines in the treatment of AWS.

References (10)

There are more references available in the full text version of this article.

Cited by (16)

  • N-methyl-D-aspartate glutamate receptors and alcoholism: Reward, dependence, treatment, and vulnerability

    2003, Pharmacology and Therapeutics
    Citation Excerpt :

    However, it is not clear yet that increased L-type VGCC receptor levels observed in animals (Guppy et al., 1995) occur in humans (Marks et al., 1989). This difference may be related to the limited clinical efficacy of L-type VGCC antagonists in human ethanol withdrawal (Altamura et al., 1990; Banger et al., 1992). The contribution of NMDA receptors to tolerance- and withdrawal-related neuroplasticity has received growing attention.

View all citing articles on Scopus
View full text